We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Smartphone App Helps Quantify Parkinson’s Disease

By HospiMedica International staff writers
Posted on 25 Apr 2018
A mobile health application uses machine learning and sensors to enable patients with Parkinson’s disease (PD) perform at-home assessments of their condition.

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA), the University of Rochester Medical Center (URMC; NY, USA), and other institutions conducted an observational study to assess the validity of a smartphone app that uses a machine-learning approach to objectively measure PD features that can be derived from five smartphone activities--voice, finger tapping, gait, balance, and reaction time--in order to generate a mobile Parkinson disease score (mPDS) on a scale of 0 to 100 (where higher scores indicate greater severity).

The study examined 6,148 patient assessments from 129 people (mean age 58.7 years; 43.4% women), both with and without PD. More...
In addition, 23 individuals with PD and 17 without PD completed standard in-person assessments during a period of six months. The main outcomes and measures were the ability of the mPDS score to identify intraday symptom fluctuations, examine how the grade score correlated with current standard PD outcome measures, and whether the mPDS grading could account for dopaminergic medication.

The results revealed that gait features contributed most to the total mPDS, at 33.4%; mPDS detected symptom fluctuations with a mean intraday change of 13.9 points on a scale of 0 to 100. The measure correlated well with The International Parkinson and Movement Disorder Society Unified Parkinson Disease’s Rating Scale, the Time Up and Go (TUG) assessment, and the Hoehn and Yahr stage tool. The mPDS improved by a mean 16.3 points in response to dopaminergic therapy. The study was published on March 26, 2018, in JAMA Neurology.

“The ability to remotely monitor patients on a much more frequent basis, more accurately track the symptoms and progression of the disease, and monitor the impact of exercise, sleep, and medications and their side effects holds the potential to transform how we treat Parkinson’s disease,” concluded study co-author Christopher Tarolli, MD, of URMC, and colleagues. “This score complements standard PD measures by providing frequent, objective, real-world assessments that could enhance clinical care and evaluation of novel therapeutics.”

PD is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. The symptoms generally come on slowly over time. Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking. Dementia becomes common in the advanced stages of the disease. Depression and anxiety are also common occurring in more than a third of people with PD. Other symptoms include sensory, sleep, and emotional problems.

Related Links:
Johns Hopkins University
University of Rochester Medical Center


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Anesthesia Cart
UTGSU-333369-DKB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The Minder Implant can record brain activity continuously for very long periods (Photo courtesy of Epiminder)

Implantable Device Continuously Monitors Brain Activity in Epileptic Patients

Epilepsy is one of the most prevalent and serious chronic neurological disorders, impacting around 52 million people globally. It is characterized by recurrent seizures, which are caused by abnormal electrical... Read more

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.